c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry

Molecular and Cellular Biology

Volumn 18, Issue 8, 1998, Pages 4499-4508

  Prall, Owen W J ^a   Rogan, Eileen M ^a   Musgrove, Elizabeth A ^a   Watts, Colin K W ^a   Sutherland, Robert L ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CYCLIN D1; CYCLIN E; ESTROGEN; FULVESTRANT; METALLOTHIONEIN; MYC PROTEIN; PROTEIN P21; REGULATOR PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE S PHASE; CROSS LINKING; ESTROGEN ACTIVITY; IMMUNOBLOTTING; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

EID: 0031877301     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.18.8.4499     Document Type: Article

References (69)

1. Adams, P. D., W. R. Sellers, S. K. Sharma, A. D. Wu, C. M. Nalin, and W. Kaelin, Jr. 1996. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell. Biol. 16:6623-6633.
2. Altucci, L., R. Addeo, L. Cicatiello, S. Dauvois, M. G. Parker, M. Truss, M. Beato, V. Sica, F. Bresciani, and A. Weisz. 1996. 17β-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G1-arrested human breast cancer cells. Oncogene 12:2315-2324.
3. Aprelikova, O., Y. Xiong, and E. T. Liu. 1995. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J. Biol. Chem. 270:18195-18197.
4. Cobrinik, D., P. Whyte, D. S. Peeper, T. Jacks, and R. A. Weinberg. 1993. Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev. 7:2392-2404.
5. Daksis, J. I., R. Y. Lu, L. M. Facchini, W. W. Marhin, and L. J. Penn. 1994. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 9:3635-3645.
6. Daly, R. J., W. H. Harris, D. Y. Wang, and P. D. Darbre. 1991. Autocrine production of insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. Cell Growth Differ. 2:457-464.
7. De Azevedo, W. F., S. Leclerc, L. Meijer, L. Havlicek, M. Strnad, and S. H. Kim. 1997. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243:518-526.
8. deFazio, A., Y.-E. Chiew, M. McEvoy, C. K. W. Watts, and R. L. Sutherland. 1997. Antisense estrogen receptor RNA expression increases epidermal growth factor receptor expression in breast cancer cells. Cell Growth Differ. 8:903-911.
9. De Luca, A., T. K. MacLachlan, L. Bagella, C. Dean, C. M. Howard, P. Paolo Claudio, A. Baldi, K. Khalili, and A. Giordano. 1997. A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 kinase activity. J. Biol. Chem. 272:20971-20974.
10. Dubik, D., T. C. Dembinski, and R. P. C. Shiu. 1987. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res. 47:6517-6521.
11. Fantl, V., G. Stamp, A. Andrews, I. Rosewell, and C. Dickson. 1995. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 9:2364-2372.
12. Foster, J. S., and J. Wimalasena. 1996. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol. 10:488-498.
13. Gu, Y., J. Rosenblatt, and D. O. Morgan. 1992. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 11:3995-4005.
14. Haas, K., P. Staller, C. Geisen, J. Bartek, M. Eilers, and T. Moroy. 1997. Mutual requirement of Cdk4 and Myc in malignant transformation: evidence for cyclin D1/Cdk4 and p16INK4A as upstream regulators of Myc. Oncogene 15:179-192.
15. Hauser, P. J., D. Agrawal, B. Chu, and W. J. Pledger. 1997. p107 and p130 associated cyclin A has altered substrate specificity. J. Biol. Chem. 272:22954-22959.
16. Henderson, B., R. Ross, and L. Bernstein. 1988. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res. 48:246-253.
17. Henriksson, M., and B. Luscher. 1996. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res. 68:109-182.
18. Hermeking, H., J. O. Funk, M. Reichert, J. W. Ellwart, and D. Eick. 1995. Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21WAF1CIP1SDI1. Oncogene 11:1409-1415.
19. Huang, T. S., J. Duyster, and J. Y. Wang. 1995. Biological response to phorbol ester determined by alternative G1 pathways. Proc. Natl. Acad. Sci. USA 92:4793-4797.
20. Jansen-Durr, P., A. Meichle, P. Steiner, M. Pagano, K. Finke, J. Botz, J. Wessbecher, G. Draetta, and M. Eilers. 1993. Differential modulation of cyclin gene expression by MYC. Proc. Natl. Acad. Sci. USA 90:3685-3689.
21. Kitagawa, M., H. Higashi, H. K. Jung, I. Suzuki-Takahashi, M. Ikeda, K. Tamai, J. Kato, K. Segawa, E. Yoshida, S. Nishimura, and Y. Taya. 1996. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J. 15:7060-7069.
22. Koff, A., F. Cross, A. Fisher, J. Schumacher, K. Leguellec, M. Philippe, and J. M. Roberts. 1991. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 66:1217-1228.
23. Leung, B. S., and A. H. Potter. 1987. Mode of estrogen action on cell proliferation in CAMA-1 cells. II. Sensitivity of G1 phase population. J. Cell. Biochem. 34:213-225.
24. Li, Y., C. Graham, S. Lacy, A. M. Duncan, and P. Whyte. 1993. The adenovirus E1A-associated 130-kD protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E. Genes Dev. 7:2366-2377.
25. Lippman, M. E., and G. Bolan. 1975. Oestrogen-responsive human breast cancer in long term tissue culture. Nature (London) 256:592-593.
26. 1 checkpoint. Mol. Cell. Biol. 16:6917-6925.
27. Mayol, X., J. Garriga, and X. Grana. 1995. Cell cycle-dependent phosphorylation of the retinoblastoma-related protein p130. Oncogene 11:801-808.
28. Mayol, X., J. Garriga, and X. Grana. 1996. G1 cyclin/CDK-independent phosphorylation and accumulation of p130 during the transition from G1 to G0 lead to its association with E2F-4. Oncogene 13:237-246.
29. Meijer, L., A. Borgne, O. Mulner, J. P. Chong, J. J. Blow, N. Inagaki, M. Inagaki, J. G. Delcros, and J. P. Moulinoux. 1997. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243:527-536.
30. Moberg, K., M. A. Starz, and J. A. Lees. 1996. E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol. Cell. Biol. 16:1436-1449.
31. Morgan, D. O. 1995. Principles of CDK regulation. Nature (London) 374: 131-134.
32. Murphy, L. J., L. C. Murphy, and H. G. Friesen. 1987. Estrogen induction of N-myc and c-myc proto-oncogene expression in the rat uterus. Endocrinology 120:1882-1888.
33. 1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA 91:8022-8026.
34. Musgrove, E. A., B. Sarcevic, and R. L. Sutherland. 1996. Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for CDK2 activation and pRB hyperphosphorylation. J. Cell. Biochem. 60:363-378.
35. 1-to-S phase transition. Mol. Cell. Biol. 15:2612-2624.
36. Perez-Roger, I., D. L. Solomon, A. Sewing, and H. Land. 1997. Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene 14:2373-2381.
37. Philipp, A., A. Schneider, I. Vasrik, K. Finke, Y. Xiong, D. Beach, K. Alitalo, and M. Eilers. 1994. Repression of cyclin D1: a novel function of MYC. Mol. Cell. Biol. 14:4032-4043.
38. Pines, J. 1995. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem. J. 308:697-711.
39. Planas-Silva, M. D., and R. A. Weinberg. 1997. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol. 17:4059-4069.
40. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66.
41. Prall, O. W. J. Unpublished data.
42. Prall, O. W. J., B. Sarcevic, E. A. Musgrove, C. K. W. Watts, and R. L. Sutherland. 1997. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J. Biol. Chem. 272:10882-10894.
43. Pusch, O., G. Bernaschek, M. Eilers, and M. Hengstschlager. 1997. Activation of c-Myc uncouples DNA replication from activation of G1-cyclin dependent kinases. Oncogene 15:649-656.
44. 1 phase in rodent fibroblasts. Genes Dev. 7:1559-1571.
45. 1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol. Cell. Biol. 14:1669-1679.
46. Riley, D. J., E. Y.-H. P. Lee, and W.-H. Lee. 1994. The retinoblastoma protein: more than a tumor suppressor. Annu. Rev. Cell Biol. 10:1-29.
47. Roussel, M. F., A. M. Theodoras, M. Pagano, and C. J. Sherr. 1995. Rescue of defective mitogenic signaling by D-type cyclins. Proc. Natl. Acad. Sci. USA 92:6837-6841.
48. Rudolph, B., R. Saffrich, J. Zwicker, B. Henglein, R. Muller, W. Ansorge, and M. Eilers. 1996. Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosis. EMBO J. 15:3065-3076.
49. 1 cyclins. Cell 73:1059-1065.
50. Sherr, C. J. 1995. D-type cyclins. Trends Biochem. Sci. 20:187-190.
51. 1 cyclin-dependent kinases. Genes Dev. 9:1149-1163.
52. Shiyanov, P., S. Bagchi, G. Adami, J. Kokontis, N. Hay, M. Arroyo, A. Morozov, and P. Raychaudhuri. 1996. p21 disrupts the interaction between cdk2 and the E2F-p130 complex. Mol. Cell. Biol. 16:737-744.
53. Sicinski, P., J. L. Donaher, S. B. Parker, T. Li, A. Fazeli, H. Gardner, S. Z. Haslam, R. T. Bronson, S. J. Elledge, and R. A. Weinberg. 1995. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621-630.
54. Solomon, D. L., A. Philipp, H. Land, and M. Eilers. 1995. Expression of cyclin D1 mRNA is not upregulated by Myc in rat fibroblasts. Oncogene 11:1893-1897.
55. Soule, H. D., and C. M. McGrath. 1980. Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice. Cancer Lett. 10:177-189.
56. 1 cyclin-cdk complexes. EMBO J. 14:4814-4826.
57. Sutherland, R. L., R. E. Hall, and I. W. Taylor. 1983. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res. 43:3998-4006.
58. Sutherland, R. L., R. R. Reddel, and M. D. Green. 1983. Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. Eur. J. Cancer Clin. Oncol. 19:307-318.
59. Sweeney, K. J., A. Swarbrick, R. L. Sutherland, and E. A. Musgrove. 1997. Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells. Oncogene 16:2865-2878.
60. Tsai, L. H., E. Lees, B. Faha, E. Harlow, and K. Riabowol. 1993. The cdk2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene 8:1593-1602.
61. Vairo, G., D. M. Livingston, and D. Ginsberg. 1995. Functional interaction between E2F-4 and p130: evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members. Genes Dev. 9:869-881.
62. van den Heuvel, S., and E. Harlow. 1993. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262:2050-2054.
63. Vlach, J., S. Hennecke, K. Alevizopoulos, D. Conti, and B. Amati. 1996. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 15:6595-6604.
64. Watson, P. H., R. T. Pon, and R. P. C. Shiu. 1991. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res. 51:3996-4000.
65. Watts, C. K. W., A. Brady, B. Sarcevic, A. deFazio, E. A. Musgrove, and R. L. Sutherland. 1995. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol. 9:1804-1813.
66. Weinberg, R. A. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-330.
67. Wilcken, N. R. C., O. W. J. Prall, E. A. Musgrove, and R. L. Sutherland. 1997. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin. Cancer Res. 3:849-854.
68. Wolf, D. A., H. Hermeking, T. Albert, T. Herzinger, P. Kind, and D. Eick. 1995. A complex between E2F and the pRb-related protein p130 is specifically targeted by the simian virus 40 large T antigen during cell transformation. Oncogene 10:2067-2078.
69. Woo, M. S., I. Sanchez, and B. D. Dynlacht. 1997. p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity. Mol. Cell. Biol. 17:3566-3579.